Neurocrine Biosciences

Neurocrine Biosciences highlighted at the Cantor Fitzgerald Healthcare Conference that the company has transformed from a one-product provider to a multi-product company with INGREZZA, CRENESSITY and VYKAT XR and recently achieved about $1 billion in quarterly revenue. The 2025 guidance of $2.85 billion was confirmed, although INGREZZA faces gradual price pressure from Medicare changes and the Inflation Reduction Act starting in 2025. Two late-stage Phase III programs (osavampator 2027, direclidin 2028) are expected to deliver key data and expand the pipeline from around three to nearly 20 programs. Management plans selective investments in commercial operations and R&D to support growth and is willing to sacrifice near-term operating margin to build long-term shareholder value. » Więcej na de.investing.com

Neurocrine Biosciences reports a record quarter with $1 billion in revenue and describes the transition from a one‑product to a diversified biopharma company with three commercial products. Ingrezza remains the main revenue driver with a 2026 forecast of $2.85 billion, CRENESSITY reached an approximate $750 million run rate about 12 months after approval, and VYKAT XR shows a $400 million run rate. Management expects pricing pressure in 2027 due to changed Medicare rebates but believes this can be offset by volume growth and market share gains, and cites several phase III data catalysts for 2027/2028; the company is debt‑free and has roughly $500 million in cash. » Więcej na de.investing.com

Neurocrine shares fell after a joint statement by three patient organizations raised safety concerns about Vykat XR, citing reports to the FDA of seven deaths and more than 100 serious adverse events. The groups did not call for a market withdrawal and did not establish causality; CEO Kyle Gano nevertheless rejected a link. Additional pressure comes from worries about price risks for INGREZZA, even though Neurocrine reported strong operational data, including record Q2 2026 sales and positive phase‑4 results for INGREZZA; the stock is likely to remain under short‑term pressure until regulators and investors gain more clarity. » Więcej na de.investing.com